Q3 2025 GeoVax Labs Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Transcript 8-K10-Q

Key Points

Positve

Geovax Labs Inc (GOVX) received guidance from the European Medicines Agency for an expedited development path for their GOMVA vaccine candidate, potentially bypassing phase 1 and phase 2 trials.
The company is experiencing increased interest from industry players and non-diluted funding organizations for partnerships and collaborations.
GOCMO4S1, their multi-antigen vaccine against COVID-19, is recognized as critically needed for immunocompromised individuals, showing potential for a robust immune response.
Geovax Labs Inc (GOVX) is actively engaging in discussions with various stakeholders, including the White House and WHO, regarding their vaccine supply and development.
The company is focused on innovative cancer therapies and infectious disease vaccines, with plans for expedited registration pathways and global commercialization.

Negative

Geovax Labs Inc (GOVX) reported a decrease in revenue to $2.5 million for the nine months ended September 30, 2025, compared to $3.1 million in 2024.
The termination of the Barda Project NextGen contract resulted in no contract revenues reported during Q3 2025.
Research and development expenses decreased, but the company still reported a net loss of $6.3 million for the quarter.
The company's cash balance decreased to $5 million as of September 30, 2025, reflecting significant cash usage in operating activities.
Geovax Labs Inc (GOVX) faces challenges in securing strategic partnerships and funding to extend their cash runway and support clinical programs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GOVX.OQ - GeoVax Labs Inc
Q3 2025 GeoVax Labs Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome everyone to the Geoax 3rd quarter 2025 corporate update call. My name is Cherie and I will facilitate today's call.

With me are David Dodd, Chairman and CEO, Mark Reynolds, Vice President, Chief Financial Officer, Mark Newman, PhD, Chief Scientific Officer, Kelly McKee, MD MPH, Chief Medical Officer, and John Sharkey, PhD, Vice President, Business Development. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.

As a reminder, this conference is being recorded. Please note the following.

Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.